Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced the appointment of Gilbert S.
for Esperion Therapeutics Announces the Appointment of Gilbert S. Omenn, M.D., Ph.D. to Board of Directors investment picks